臨床婦人科産科73巻12号

2019年12月発行

今月の臨床 産婦人科領域で話題の新技術―時代の潮流に乗り遅れないための羅針盤

Part2 : 注目の最新技術 【腫瘍】

新規腫瘍マーカーHE4とROMAによる卵巣がん診断

著者： 永石匡司¹²

所属機関： ¹日本大学医学部産婦人科学系産婦人科学分野 ²日本大学病院産婦人科

ページ範囲：P.1235 - P.1241

文献概要

●卵巣がん診断の補助として保険収載された新規腫瘍マーカーHE4は卵巣がん患者で高値を示し，なかでも進行がんでより高値となる．

●HE4は月経周期や妊娠などの影響を受けづらく，子宮内膜症との鑑別にも有効である．CA125と比べて感度は低いが特異度は高い．

●CA125とHE4の組み合わせにより卵巣がんの診断能は向上する．特に卵巣悪性腫瘍推定値ROMAが有用で，これはFDAにも承認され，国内でも薬事承認を受けている．

●HE4やROMAは，特に進展が急速な高異型度漿液性癌の診断に有効であるが，非漿液性癌ではやや劣る傾向にある．

参考文献

1）国立がん研究センターがん対策情報センター : がん情報サービス「がん登録・統計」（https://ganjoho.jp/reg_stat/）

2）Heintz AP, et al : Carcinoma of the Ovary. Int J Gynecol Obstet 95 : S161-S192, 2006

3）Hogg R, et al : Biology of epithelial ovarian cancer : implications for screening women at high genetic risk. J Clin Oncol 22 : 1315-1327, 2004

4）Kobayashi H, et al : Risk of developing ovarian cancer among women with ovarian endometrioma : a cohort study in Shizuoka, Japan. Int J Gynecol Cancer 17 : 37-43, 2007

5）Hellström I, et al : The HE4（WFDC2）protein is a biomarker for ovarian carcinoma. Cancer Res 63 : 3695-3700, 2003

6）Sölétormos G, et al : Clinical use of cancer biomarkers in epithelial ovarian cancer : updated guidelines from the European group on tumor markers. Int J Gynecol Cancer 26 : 43-51, 2016

7）Jacobs I, et al : A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. B J Obstet Gynecol 97 : 922-929, 1990

8）Buys SS, et al : Effect of screening on ovarian cancer mortality : the prostate, lung, colorectal and ovarian（PLCO）cancer screening randomized controlled trial. JAMA 305 : 2295-2303, 2011

9）Jacobs IJ, et al : Ovarian cancer screening and mortality in the UK collaborative trial of ovarian cancer screening（UKCTOCS）: a randomised controlled trial. Lancet 387 : 945-956, 2016

10）Anastasi E, et al : Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women. Tumor Biol 31 : 411-415, 2010

11）Bolstad N, et al : Human epididymis protein 4 reference limits and natural variation in a Nordic reference population. Tumor Biol 33 : 141-148, 2012

12）HE4．アボット社添付文書，2016

13）Shinae Y : Diagnostic performance and establishment of reference limits of HE4 in Korean healthy women. Gynecol Oncol 143 : 128-134, 2016

14）Kirchhoff C, et al : A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod 45 : 350-377, 1991

15）Drapkin R, et al : Human epididymis protein 4（HE4）is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 65 : 2162-2169, 2005

16）Fujiwara H, et al : Evaluation of human epididymis protein 4（HE4） and risk of ovarian malignancy algorithm（ROMA） as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women. Tumor Biol 36 : 1045-1053, 2015

17）Huhtinen K, et al : Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. B J Cancer 100 : 1315-1319, 2009

18）Scholler N, et al : Bead-based ELISA for validation of ovarian cancer early detection markers. Clin Cancer Res 12 : 2117-2124, 2006

19）Moore RG, et al : The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 108 : 402-408, 2008

20）Moore RG, et al : A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 112 : 40-46, 2009

21）Molina R, et al : HE4 a novel tumour marker for ovarian cancer : comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumor Biol 32 : 1087-1095, 2011

22）Dayyani F, et al : Diagnostic performance of risk of ovarian malignancy algorithm against CA125 and HE4 in connection with ovarian cancer : a meta-analysis. Int J Gynecol Cancer 26 : 1586-1593, 2016

23）Ikeda Y, et al : The risk of ovarian malignancy algorithm（ROMA） as a predictive marker of peritoneal dissemination in epithelial ovarian cancer patients. Oncol Res Treat 38 : 276-281, 2015

24）Karlsen MA, et al : A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer-An international multicenter study in women with an ovarian mass. Gynecol Oncol 138 : 640-646, 2015

25）Piovano E, et al : The role of HE4 in ovarian cancer follow-up : a review. Int J Gynecol Cancer 24 : 1359-1365, 2014

26）Zhu L, et al : Overexpression of HE4（human epididymis protein 4）enhances proliferation, invasion and metastasis of ovarian cancer. Oncotarget 7 : 729-744, 2016

27）Hu L,et al : Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in endometrial cancer : a meta-analysis. Int J Gynecol Cancer 26 : 331-340, 2016